Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

• Status: Enrolling by invitation
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria

Informed subject consent will be obtained from those patients meeting the following inclusion criteria:

• Male and female patients 18 years or older.

• Clinical and/or histopathological diagnosis of PRP

• Candidate for systemic therapy (PASI ≥ 10)

• Body surface area of involvement ≥ 10%

• Good general health as confirmed by medical history

• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and

• Patients who read and sign an approved informed consent for this study

Exclusion Criteria

Patients are to be excluded based on the following criteria:

• Vulnerable study population

• Pregnant or nursing women

• Women planning a pregnancy within the study period

• Human immunodeficiency virus (HIV) positivity

• Known history of adverse reaction to Cosentyx

• Known history of hepatitis B, hepatitis C, or tuberculosis

• Personal or family history of inflammatory bowel disease